Advertisement

De Novo, Progressed, and Neglected Metastatic Castration-Sensitive Prostate Cancer: Is One Therapy Fit for All?

      Abstract

      Patients who receive a diagnosis of metastatic castration-sensitive prostate cancer (CSPC) have different phenotypes of disease. Some of them have de novo CSPC, but others receive a late diagnosis, and still others underwent prostatectomy several years before the diagnosis of metastases. We analyze the presence of these differences in recent clinical trials in CSPC and assess the possible impact on their results.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sweeney C.J.
        • Chen Y.H.
        • Carducci M.
        • et al.
        Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.
        N Engl J Med. 2015; 373: 737-746
        • Fizazi K.
        • Tran N.
        • Fein L.
        • et al.
        Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer.
        N Engl J Med. 2017; 377: 352-360
        • James N.D.
        • Sydes M.R.
        • Clarke N.W.
        • et al.
        Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
        Lancet. 2016; 387: 1163-1177
        • James N.D.
        • de Bono J.S.
        • Spears M.R.
        • et al.
        Abiraterone for prostate cancer not previously treated with hormone therapy.
        N Engl J Med. 2017; 377: 338-351
        • Finianos A.
        • Gupta K.
        • Clark B.
        • Simmens S.J.
        • Aragon-Ching J.B.
        Characterization of differences between prostate cancer patients presenting with de novo versus primary progressive metastatic disease.
        Clin Genitourin Cancer. 2017; ([Epub ahead of print])https://doi.org/10.1016/j.clgc.2017.08.006
        • Ost P.
        • Reynders D.
        • Decaestecker K.
        • et al.
        Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial.
        J Clin Oncol. 2018; 36: 446-453
        • Yassaie O.
        • McLaughlin B.
        • Perera M.
        • Manning T.
        • Lawrentschuk N.
        • Malcolm A.
        Primary care follow-up of radical prostatectomy patients: a regional New Zealand experience.
        Prostate Int. 2016; 4: 136-139
        • Freedland S.J.
        • Humphreys E.B.
        • Mangold L.A.
        • Eisenberger M.
        • Partin A.W.
        Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.
        J Urol. 2006; 176: 1404-1408
        • Freedland S.J.
        • Humphreys E.B.
        • Mangold L.A.
        • et al.
        Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality.
        J Clin Oncol. 2007; 25: 1765-1771
        • Chen S.L.
        • Wang S.C.
        • Ho C.J.
        • et al.
        Prostate cancer mortality-to-incidence ratios are associated with cancer care disparities in 35 countries.
        Sci Rep. 2017; 7: 40003
        • Moses K.A.
        • Paciorek A.T.
        • Penson D.F.
        • Carroll P.R.
        • Master V.A.
        Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE.
        J Clin Oncol. 2010; 28: 1069-1074
        • O’Keefe E.B.
        • Meltzer J.P.
        • Bethea T.N.
        Health disparities and cancer: racial disparities in cancer mortality in the United States, 2000-2010.
        Front Public Health. 2015; 3: 51
        • Baade P.D.
        • Youlden D.R.
        • Cramb S.M.
        • Dunn J.
        • Gardiner R.A.
        Epidemiology of prostate cancer in the Asia-Pacific region.
        Prostate Int. 2013; 1: 47-58
        • Ye D.
        • Huang Y.
        • Zhou F.
        • et al.
        A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia.
        Asian J Urol. 2017; 4: 75-85
        • Sun Y.
        • Zou Q.
        • Sun Z.
        • et al.
        Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: a randomized, double-blind, placebo-controlled phase 3 bridging study.
        Int J Urol. 2016; 23: 404-411
        • Fizazi K.
        • Tran N.
        • Fein L.E.
        • et al.
        Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naïve prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial.
        J Clin Oncol. 2018; 36 (Abstract 182)
        • Gravis G.
        • Boher J.M.
        • Chen Y.H.
        • et al.
        Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies.
        Eur Urol. 2018; 73: 847-855